DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium

Virchows Archiv

Volumn 461, Issue 3, 2012, Pages 291-298

  Pradhan, Manohar ^a,b   Davidson, Ben ^a,c   Abeler, Vera Maria ^a   Danielsen, Håvard Emil ^a,b   Tropé, Claes Göran ^a,c   Kristensen, Gunnar Balle ^a   Risberg, Björn Åke ^a,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

DNA ploidy; Endometrial carcinoma; Estrogen receptor; p53; Progesterone receptor; Serous adenocarcinoma

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIPLOIDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMAGE CYTOMETRY; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MYOMETRIUM; OVERALL SURVIVAL; PLOIDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TETRAPLOIDY;

AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; IMAGE CYTOMETRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NORWAY; PLOIDIES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84867400480     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1275-2     Document Type: Article

References (33)

1. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R (1982) Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6:93-108 (Pubitemid 12108965)
2. Lauchlan SC (1981) Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med 105:615-618 (Pubitemid 11020875)
3. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S (2006) Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95(Suppl 1):S105-S143
4. Hamilton CA, Kapp DS, Chan JK (2008) Clinical aspects of uterine papillary serous carcinoma. Curr Opin Obstet Gynecol 20:26-33
5. Abeler VM, Kjørstad KE (1990) Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. Gynecol Oncol 39:266-271
6. Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D (2001) Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 22:122-126 (Pubitemid 32963063)
7. Sherman ME, Bur ME, Kurman RJ (1995) p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 26:1268-1274
8. Kallakury BV, Ambros RA, Hayner-Buchan AM, Sheehan CE, Malfetano JH, Ross JS (1998) Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes. Int J Gynecol Pathol 17:320-326 (Pubitemid 28447160)
9. Lax SF (2004) Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444:213-223 (Pubitemid 38446432)
10. Chen Y, Yao Y, Zhang L, Li X, Wang Y, Zhao L, Wang J, Wang G, Shen D, Wei L, Zhao J (2011) cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer. Exp Mol Pathol 91:373-384
11. Pradhan M, Abeler VM, Danielsen HE, Tropé CG, Risberg BÅ (2006) Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. Mod Pathol 19:1227-1235 (Pubitemid 44268193)
12. Sood BM, Jones J, Gupta S, Khabele D, Guha C, Runowicz C, Goldberg G, Fields A, Anderson P, Vikram B (2003) Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys 57:208-216 (Pubitemid 36959758)
13. Pradhan M, Abeler VM, Danielsen HE, Sandstad B, Tropé CG, Kristensen GB, Risberg BÅ (2012) Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium. Ann Oncol 23:1178-84
14. Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA, Tavassoli FA (2003) Tumours of uterine corpus. In: Tavassoli FA, Devilee P (eds) World Health Organization Classification of Tumours: Pathology and Genetics. Tumours of the breast and female genital organs. IARC Press, Lyon, pp 218-232
15. Baak JP, Snijders W, Van Diermen B, Van Diest PJ, Diepenhorst FW, Benraadt J (2003) Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in international Federation of gynecology and obstetrics stage 1 and 2 endometrial carcinoma. J Clin Oncol 21:4214-4221 (Pubitemid 46606191)
16. Strang P, Stenkvist B, Bergström R, Stendahl U, Valdes C, Tribukait B (1991) Flow cytometry and interactive image cytometry in endometrial carcinoma. A comparative and prognostic study. Anticancer Res 11:783-788
17. Grote HJ, Friedrichs N, Pomjanski N, Guhde HF, Reich O, Böcking A (2001) Prognostic significance of DNA cytometry in carcinoma of the uterine cervix FIGO stage IB and II. Anal Cell Pathol 23:97-105 (Pubitemid 34621774)
18. Maounis NF, Chorti M, Apostolakis E, Ellina E, Blana A, Aggelidou M, Dritsas I, Markidou S (2006) Prognostic impact of deoxyribonucleic acid (DNA) image analysis cytometry and immunohistochemical expression of Ki67 in surgically resected non-small cell lung cancers. Cancer Detect Prev 30:507-514 (Pubitemid 44828289)
19. Onguru O, Ulutin C, Celasun B, Gunhan O (2003) DNA ploidy and nuclear morphometry in adult intracranial ependymomas. Clin Neuropathol 22:266-272 (Pubitemid 37541365)
20. Raatz H, Böcking A, Hauptmann S (2004) Prognostic impact of DNA-image-cytometry in neuroendocrine (carcinoid) tumours. Cell Oncol 26:81-88 (Pubitemid 39108246)
21. Kato DT, Ferry JA, Goodman A, Sullinger J, Scully RE, Goff BA, Fuller AF Jr, Rice LW (1995) Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol 59:384-389
22. Garg K, Leitao MM Jr, Wynveen CA, Sica GL, Shia J, Shi W, Soslow RA (2010) p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol 23:80-92
23. Faratian D, Stillie A, Busby-Earle RM, Cowie VJ, Monaghan H (2006) A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome. Int J Gynecol Cancer 16:972-978 (Pubitemid 43886712)
24. Murray SK, Young RH, Scully RE (2000) Uterine endometrioid carcinoma with small nonvillous papillae: an analysis of 26 cases of a favorable-prognosis tumor to be distinguished from serous carcinoma. Int J Surg Pathol 8:279-289 (Pubitemid 32120690)
25. Nordström B, Strang P, Lindgren A, Bergström R, Tribukait B (1996) Carcinoma of the endometrium: do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications? Int J Gynecol Pathol 15:191-201 (Pubitemid 26227276)
26. Clement PB, Young RH (2004) Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 11:117-142
27. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z (2008) The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 32:304-315 (Pubitemid 351172146)
28. Abeler VM, Kjørstad KE (1991) Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 67:3093-3103
29. Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, Cain JM, Tamimi HK, Figge DC, Greer BE (1994) Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 54:264-268 (Pubitemid 24301898)
30. Mineta H, Borg A, Dictor M, Wahlberg P, Akervall J, Wennerberg J (1998) p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer 78:1084-1090 (Pubitemid 28463987)
31. Salvesen HB, Iversen OE, Akslen LA (1999) Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 17:1382-1390 (Pubitemid 29220843)
32. Alkushi A, Lim P, Quino-Parsons C, Gilks CB (2002) Markers of proliferative activity are predictors of patient outcome for lowgrade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Mod Pathol 15:365-371 (Pubitemid 34326943)
33. Alkushi A, Kobel M, Kalloger SE, Gilks CB (2010) High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol 29:343-350